Related Experiment Video
Updated: Jun 2, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective
Qian Qian1, Ping Zhan, Like Yu
1Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, China.
Clinical Lung Cancer
|May 10, 2011
Summary
Serum soluble intercellular adhesion molecule-1 (sICAM-1) levels predict chemotherapy effectiveness and survival in advanced non-small-cell lung cancer (NSCLC) patients. Baseline sICAM-1 and its response during treatment are reliable prognostic markers.
Area of Science:
- Oncology
- Biomarkers
- Cancer Research
Background:
- Advanced non-small-cell lung cancer (NSCLC) presents challenges in predicting chemotherapy response.
- Serum biomarkers are explored for their potential predictive and prognostic roles.
Purpose of the Study:
- To assess the predictive and prognostic significance of serum soluble intercellular adhesion molecule-1 (sICAM-1) and vascular endothelial growth factor (VEGF) in advanced NSCLC patients undergoing chemotherapy.
- To evaluate these markers as potential indicators of treatment efficacy and patient survival.
Main Methods:
- Prospective study of 124 advanced NSCLC patients receiving first-line conventional chemotherapy.
- Serum sICAM-1 and VEGF levels measured using enzyme-linked immunosorbent assay at baseline and after every two chemotherapy courses.
- Correlation of biomarker changes with radiologic objective response and patient survival.
Main Results:
- Baseline sICAM-1 levels (cutoff > 232.84 ng/mL) and sICAM-1 response showed statistically significant correlations with odds ratios.
- VEGF levels did not correlate with odds ratios.
- Multivariate analysis identified baseline sICAM-1 and sICAM-1 response as independent prognostic factors for survival, alongside performance status and disease stage.
Conclusions:
- Serum sICAM-1 levels at baseline and their changes during chemotherapy are reliable surrogate markers for predicting chemotherapy efficacy in advanced NSCLC.
- sICAM-1 serves as a significant prognostic factor for survival in these patients.